Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 12/20 | 0.55 |
| ▸ | LY96 | Q9Y6Y9 | 6/20 | 0.53 |
| ▸ | PYGB | P11216 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25835401 | 0.97 | TLR4 (0.53) | TLR4LY96PYGBMAPK1LGALS8 | |
| SCHEMBL21137862 | 0.91 | PYGB (0.49) | TLR4LY96PYGBMAPK1LGALS8 | |
| SCHEMBL21138210 | 0.91 | PYGB (0.52) | TLR4LY96PYGBMAPK1LGALS8 | |
| SCHEMBL21137907 | 0.87 | TLR4 (0.55) | TLR4LY96PYGBL3MBTL1LGALS8 | |
| SCHEMBL21137941 | 0.81 | MAPT (0.42) | TLR4LY96PYGBMAPK1L3MBTL1 | |
| SCHEMBL17793805 | 0.80 | TLR4 (0.65) | TLR4LY96PYGBLGALS8LMNA | |
| SCHEMBL2338181 | 0.80 | TLR4 (0.65) | TLR4LY96PYGBLGALS8LMNA | |
| SCHEMBL12391271 | 0.80 | TLR4 (0.65) | TLR4LY96PYGBLGALS8LMNA | |
| SCHEMBL21137921 | 0.80 | TLR4 (0.58) | TLR4LY96PYGBMAPK1LGALS8 | |
| SCHEMBL6800437 | 0.79 | TLR4 (0.60) | TLR4LY96 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | TLR4 660/4885LY96 3733/4885PYGB 760/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | TLR4 896/4885LY96 3825/4885PYGB 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.